IP AUSTRALIA
AUSTRALIAN PATENT OFFICE
Merck, Sharpe & Dohme (Australia) Pty Ltd. v Genentech, Inc. [2015] APO 19
Patent Application: 2003287257
Title:Inhibition of IL-17 production
Patent Applicant: Genentech, Inc.
Opponent: Merck, Sharpe & Dohme (Australia) Pty Ltd.
Delegate: Dr B. Akhurst
Decision Date: 12 May 2015
Hearing Date: 23 February 2015, in Canberra
Catchwords: PATENTS – Final determination of an opposition under section 59 – the earlier hearing was conducted, and the decision made, on the basis of the independent claims with no detailed submissions or consideration with respect to the dependent claims ‑ the specific deficiencies to be overcome for all claims found invalid are those explicitly identified in the earlier decision – if a ground of opposition could have been pursued at the earlier hearing with respect to a feature in a dependent claim then introduction of this feature into an independent claim does not introduce a new deficiency – the amendments overcome the deficiencies identified in the earlier decision and do not introduce new deficiencies
Representation: Patent applicant: Andrew Fox of Counsel, instructed by Dr Stuart Boyer patent attorney of Griffith Hack, Perth.
Opponent: Matthew Darke of Counsel, instructed by Andrew Blattmann and Simon Potter patent attorneys of Spruson & Ferguson, Sydney.
IP AUSTRALIA
AUSTRALIAN PATENT OFFICE
Patent Application: 2003287257
Title:Inhibition of IL-17 production
Patent Applicant: Genentech, Inc.
Date of Decision: 12 May 2015
DECISION
The amendments to the specification overcome the deficiencies identified in the earlier decision and do not introduce new deficiencies. Therefore, subject to an appeal of this decision, I direct the application proceed to grant.
Costs according to Schedule 8 are awarded against Merck, Sharpe & Dohme (Australia) Pty Ltd.
REASONS FOR DECISION
Background
Patent application 2003287257 in the name of Genentech, Inc. (Genentech) was advertised as accepted on 10 December 2009. Merck, Sharpe & Dohme (Australia) Pty Ltd. (MSDA) opposed the grant of a patent under s. 59 and the matter was heard on 12 November 2013 (the earlier hearing). On 6 February 2014, my decision that the opposition succeeded on the grounds of novelty and fair basis was reported as [2014] APO 6 (the earlier decision). Although the opposition was successful, I believed it was possible to overcome the deficiencies in the claims and I provided Genentech with 2 months in which to propose suitable amendments under s. 104. Genentech’s amendments on 4 April 2014 (the amendments) were allowed unopposed on 13 November 2014.
After receiving advice that the opposition was due for final determination, MSDA requested a hearing and the date was set. MSDA’s summary of submissions was filed on 13 February 2015 and Genentech’s on 20 February 2015. It was apparent from MSDA’s summary that it intended to pursue the grounds of novelty and inventive step on the basis of a particularised document not raised in the earlier hearing. Thus, on 16 February 2015, the delegate reminded the parties of the nature of a final determination hearing as follows:
“It is…
Keep reading for free
Create a free CaseChat account to read Merck, Sharpe & Dohme (Australia) Pty Ltd. v Genentech, Inc and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2015] APO 19
- Decision Date
CaseChat Overview and Summary
The legal issues before the court were whether the deficiencies identified in the earlier hearing concerning the validity of the dependent claims applied equally to the amended independent claims and whether the introduction of features from the dependent claims into the independent claims constituted new deficiencies. The central question was whether the specific deficiencies identified in the earlier decision could be overcome by the amendments and whether these amendments introduced any new deficiencies that had not been previously considered.
The court determined that the deficiencies identified in the earlier decision concerning the dependent claims should be applied to the amended independent claims. The court held that if a ground of opposition could have been pursued at the earlier hearing with respect to a feature in a dependent claim, then the introduction of this feature into an independent claim did not introduce a new deficiency. The court further found that the amendments made to the independent claims overcame the deficiencies identified in the earlier decision and did not introduce any new deficiencies.
In conclusion, the court ruled in favour of Genentech, Inc., finding that the amended independent claims were valid. The final orders of the court upheld the validity of the amended claims and dismissed the opposition brought by Merck, Sharpe & Dohme (Australia) Pty Ltd.
Orders
Orders of the court
Background
Background to the litigation
Evidence
Evidence Before The Court
Decision
Reasons for decision
Ratio Decidendi